🧬 Aging Wiki

Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis

4 min read

⚠️ Auto-extracted by Claude on 2026-06-25 — not verifiable against full text: closed-access (JACC, DOI 10.1016/j.jacc.2012.09.017), full text not retrievable. The headline quantitative results below (54.5% per-mmol/L CHD reduction, 95% CI, n, p-value, 3-fold comparison) are transcribed from the published abstract and are abstract-confirmed; numbers internal to the body (per-gene effect estimates, individual cohort weights) are not. gap/no-fulltext-access

Ference et al. 2012 — Lifetime LDL exposure and CHD risk (Mendelian randomization)

The foundational Mendelian-randomization meta-analysis establishing that the cardiovascular benefit of lower LDL-C is a function of cumulative lifetime exposure, not just current level — and quantifying it: each unit of lifelong genetically-lower LDL-C confers roughly three times the coronary-heart-disease (CHD) risk reduction of the same LDL-C drop achieved by a statin started in middle age.

This is the primary source for the “~3× greater lifetime LDL benefit” claim that recurs across this wiki (apob, ldlr, crispr-base-editing-pcsk9, statins) and the quantitative cornerstone of the cumulative-exposure / “LDL-years” model of atherosclerosis.

Design

A two-stage Mendelian-randomization synthesis 1:

  1. A series of meta-analyses estimating the CHD effect of lower LDL-C mediated by 9 polymorphisms in 6 genes (natural genetic instruments for lifelong-lower LDL-C).
  2. A combined meta-analysis of non-overlapping data (312,321 participants) yielding a single pooled estimate, compared against the per-unit benefit observed in statin treatment trials initiated later in life.

Using germline variants as instruments approximates lifelong random allocation to lower LDL-C — combining the unconfoundedness of randomization with a decades-long exposure window no RCT can deliver.

Key results

QuantityValue
Pooled CHD risk reduction per 1 mmol/L (38.7 mg/dL) lower LDL-C54.5% (95% CI 48.8%–59.5%)
Heterogeneity across the 9 instrumentsI² = 0.0% (no detectable heterogeneity)
Magnitude vs. statin started later in life~3-fold greater per unit LDL-C
Significance of the differencep = 8.43 × 10⁻¹⁹
Combined sample312,321 participants

The ~22% per-mmol/L proportional CHD reduction seen in statin RCTs (treatment beginning in mid-/late life) contrasts with the ~54.5% per-mmol/L reduction from lifelong genetically-lower LDL-C — the basis of the 3-fold framing.

Why it matters here

  • Causality + dose-timing, not just dose. Atherosclerosis integrates ApoB-particle exposure over decades; the same absolute LDL-C reduction buys far more risk reduction the earlier and more durably it is applied. This is the geroprotective rationale for one-and-done lifelong LDL lowering — the explicit design argument for somatic PCSK9 base editing (recapitulating a lifelong loss-of-function phenotype from a single adult dose).
  • Supersedes a closed-access secondary cite. Several pages previously sourced the “~3×” figure to Ference’s 2024 Nature Reviews Cardiology review (closed-access, unverifiable). This 2012 paper is the primary, with the headline number abstract-confirmed (CI + p-value). The 2024 review remains a useful framing/context citation but is no longer the load-bearing source for the quantitative claim.

Caveats

  • Closed-access; only the abstract is confirmable. The per-gene instrument estimates and cohort-level weights inside the paper are not independently checked — gap/no-fulltext-access.
  • MR estimates the effect of lifelong exposure; they should not be read as the expected benefit of an LDL reduction initiated in adulthood — that is precisely the point of the 3-fold gap. Extrapolating the 54.5% figure to a drug started at 50 would overstate achievable benefit.
  • Consistent with, and complementary to, 2 (PCSK9 loss-of-function carriers) and the later HMGCR/NPC1L1 MR work (Ference 2015) — convergent natural-experiment evidence for LDL causality.

Citations

Footnotes

  1. ference-2012-ldl-mr-lifetime · doi:10.1016/j.jacc.2012.09.017 · Ference BA, Yoo W, Alesh I, et al. · JACC 2012;60(25):2631–2639 · PMID 23083789 · n=312,321 · Mendelian randomization meta-analysis (9 polymorphisms / 6 genes) · model: human genetics · 54.5% (95% CI 48.8–59.5%) CHD reduction per 1 mmol/L lower lifelong LDL-C, ~3× the statin per-unit effect, p=8.43×10⁻¹⁹, I²=0.0% · closed-access, abstract-confirmed. ↩

  2. doi:10.1056/NEJMoa054013 · Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH · N Engl J Med 2006;354(12):1264–1272 · observational (MR-equivalent); ARIC cohort · PCSK9 nonsense-allele carriers: ~28% lower LDL-C, 47–88% lower CHD risk · the lifelong-PCSK9-LOF natural experiment. ↩

Graph View

Backlinks